Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab with Focal Radiotherapy in Platinum-Resistant Ovarian Cancer
NCT03283943Phase 1Unknown
- Sponsor
- BC Cancer
- Start
- Apr 2018
- Primary completion
- Dec 2020
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of durvalumab in ovarian cancer, primary peritoneal carcinoma (PPC) and fallopian tube cancer (PFTC), sponsored by BC Cancer. Primary endpoint: Maximum Tolerated Dose at 4 weeks. Status: unknown.
02
Drugs
durvalumab
03
Conditions
ovarian cancerprimary peritoneal carcinoma (PPC)fallopian tube cancer (PFTC)
Beyond the preview
Go deeper on NCT03283943.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03283943.